Novartis Beats Q2 2026 Expectations as New Drugs Offset Generic Pressure

Novartis reported strong Q2 2026 results with $14.41B sales and a core profit beat, driven by Kisqali (+43%) and Scemblix. Full-year guidance reaffirmed despite Entresto patent cliff.